Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CSL112 in Acute Coronary Syndrome
NCT03473223Phase 3Completed
- Sponsor
- CSL Limited
- Start
- Mar 2018
- Primary completion
- Feb 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 49
01
Overview
A Phase 3 trial of CSL112 in acute coronary syndrome (ACS), sponsored by CSL Limited. Started Mar 2018; status: completed.
02
Drugs
CSL112
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on NCT03473223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03473223.